Review




Structured Review

Pharmakon Pharmaceuticals Inc pharmakon 1760 compound library
Response of a subset <t>of</t> <t>Pharmakon-1760</t> compounds in cytochrome c 4 assays. Heme stains of SDS-PAGE gels are shown, with the heme-stained band detecting heme attachment mediated by the indicated cyt c biogenesis system. Candidate inhibitors are shown in red. ( A ) Recombinant E. coli Δ ccm with System I producing cyt c 4 in the presence of the listed drugs. ( B ) Recombinant E. coli Δ ccm with System II producing cyt c 4 . Rifampicin (green font) is a transcriptional inhibitor in the Pharmakon-1760 library that inhibits protein expression. kD refers to the molecular weights, with 20 kDa and 25 kDa markers shown.
Pharmakon 1760 Compound Library, supplied by Pharmakon Pharmaceuticals Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/1760+compound+comprising+library+pharmakon/pmc13170271-59-1-1
Average 86 stars, based on 1 article reviews
pharmakon 1760 compound library - by Bioz Stars, 2026-11
86/100 stars

Images

1) Product Images from "Inhibitors of cytochrome c biogenesis pathways"

Article Title: Inhibitors of cytochrome c biogenesis pathways

Journal: mBio

doi: 10.1128/mbio.00273-26

Response of a subset of Pharmakon-1760 compounds in cytochrome c 4 assays. Heme stains of SDS-PAGE gels are shown, with the heme-stained band detecting heme attachment mediated by the indicated cyt c biogenesis system. Candidate inhibitors are shown in red. ( A ) Recombinant E. coli Δ ccm with System I producing cyt c 4 in the presence of the listed drugs. ( B ) Recombinant E. coli Δ ccm with System II producing cyt c 4 . Rifampicin (green font) is a transcriptional inhibitor in the Pharmakon-1760 library that inhibits protein expression. kD refers to the molecular weights, with 20 kDa and 25 kDa markers shown.
Figure Legend Snippet: Response of a subset of Pharmakon-1760 compounds in cytochrome c 4 assays. Heme stains of SDS-PAGE gels are shown, with the heme-stained band detecting heme attachment mediated by the indicated cyt c biogenesis system. Candidate inhibitors are shown in red. ( A ) Recombinant E. coli Δ ccm with System I producing cyt c 4 in the presence of the listed drugs. ( B ) Recombinant E. coli Δ ccm with System II producing cyt c 4 . Rifampicin (green font) is a transcriptional inhibitor in the Pharmakon-1760 library that inhibits protein expression. kD refers to the molecular weights, with 20 kDa and 25 kDa markers shown.

Techniques Used: SDS Page, Staining, Recombinant, Expressing

Related Articles

Drug discovery:

Article Title: Inhibitors of cytochrome c biogenesis pathways
Article Snippet: .. The Pharmakon-1760 compound library, described in the Materials and Methods section, was used to screen for inhibitors of cyt c biogenesis Systems I and II. ..



Similar Products

95
TargetMol clinical stage compounds
Clinical Stage Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/Clinical+Compound+Library/10__1021_slash_acs__jmedchem__6c01726-423-7-11
Average 95 stars, based on 1 article reviews
clinical stage compounds - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Selleck Chemicals natural terpenoid compound library
Primary screening of a <t>terpenoid</t> <t>compound</t> <t>library</t> against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.
Natural Terpenoid Compound Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/Compound/pmc13748739-35-1-11
Average 96 stars, based on 1 article reviews
natural terpenoid compound library - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

90
TargetMol anti cardiovascular disease compound library
Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Anti Cardiovascular Disease Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/Anti-Cardiovascular+Disease+Compound+Library/pmc13748904-58-22-21
Average 90 stars, based on 1 article reviews
anti cardiovascular disease compound library - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

96
TargetMol pharmacopeia compound library
Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Pharmacopeia Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/FDA-Approved+Drug+Library/10__1038_slash_s41419___026___09401___w-74-10-7
Average 96 stars, based on 1 article reviews
pharmacopeia compound library - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Selleck Chemicals compound library
Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Compound Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/Compound/pm42969951-217-1-11
Average 96 stars, based on 1 article reviews
compound library - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Selleck Chemicals diverse compound libraries
Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Diverse Compound Libraries, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/Compound/pm42968518-55-2-31
Average 96 stars, based on 1 article reviews
diverse compound libraries - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
TargetMol compound library
Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/Clinical+Compound+Library/pm42966158-42-0-11
Average 95 stars, based on 1 article reviews
compound library - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

97
TargetMol custom bioactive compound library
Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Custom Bioactive Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/Bioactive+Compound+Library/pm42933337-145-13-17
Average 97 stars, based on 1 article reviews
custom bioactive compound library - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

94
Selleck Chemicals organoid based drug screening
Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Organoid Based Drug Screening, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/Epigenetics+Compound+Library/pmc13683295-285-4-13
Average 94 stars, based on 1 article reviews
organoid based drug screening - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
TargetMol drug screen
Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Drug Screen, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+libraries/Cell+Cycle+Compound+Library/pm42901431-305-15-20
Average 94 stars, based on 1 article reviews
drug screen - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Primary screening of a terpenoid compound library against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.

Journal: JAC-Antimicrobial Resistance

Article Title: Identification of valepotriate as a novel antimycobacterial agent against drug-resistant Mycobacterium tuberculosis through screening of a natural terpenoid compound library

doi: 10.1093/jacamr/dlag250

Figure Lengend Snippet: Primary screening of a terpenoid compound library against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.

Article Snippet: A natural terpenoid compound library containing 354 compounds was purchased from Selleck Chemicals (L1420, Selleck Chemicals, USA).

Techniques: Screening, Drug discovery, Cell Culture, Concentration Assay, Inhibition, Bacteria, Negative Control, Positive Control

Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: Advanced Science

Article Title: Targeting a Calcium‐Associated Mitochondrial Vulnerability in TET2‐Deficient Myeloid Cells

doi: 10.1002/advs.78748

Figure Lengend Snippet: Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: To identify compounds that preferentially compromise TET2 ‐KD macrophages, we performed chemical‐genetic screening using 489 cardiovascular disease‐related bioactive compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library (Figure and Extended Data Table ).

Techniques: Screening, Derivative Assay, Drug discovery, Preserving, Biomarker Discovery, Alamar Blue Assay, Activity Assay, MTS Assay, Transfection, Enzyme-linked Immunosorbent Assay, RNA Sequencing